CARsgen (科济药业) IPO: Not the Best Deal but Will Be Decent
In this note, we provide an update for the CARsgen's book building. We think there will be at least a 24% upside at the high end and the allocation...
320 Views
CARsgen Therapeutics IPO: Valuation Insights
Due to the full IPO price range, lack of blue-chip cornerstone support and the current weak market sentiment on IPOs, we are inclined to wait on...
443 Views
ECM Weekly (30th May 2021) - JD Log, Monde Nissin, Weilong Deli, Kanzhun, CARsgen, WM Tech, Novotech
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
312 Views
CARSgen Therapeutics IPO: Catalyzing Cancer Therapies
CARSgen’s core product CT053 shows significant potential given its positive ORR and receiving the US FDA RMAT designation.
399 Views
CARsgen Therapeutics IPO Initiation: Choosing Therapies À La CAR-T
CARsgen is pre-marketing an HKEx IPO to raise proceeds of $400-500m. The promising prospects for the lead product, credible management and a good...
333 Views